Want to see BLSM full AI Analyst Report?

BlossomHill Therapeutics, Inc. (BLSM) Price & Analysis

15 Followers

BLSM Stock Chart & Stats

$22.34

-$2.91(-11.52%)

Sep 23, 2026

―

Day’s Range― - ―

52-Week Range$15.25 - $27.99

Previous CloseN/A

VolumeN/A

Average Volume (3M)215.29K

Market Cap

$802.57M

Enterprise ValueN/A

Total Cash (Recent Filing)$95.38M

Total Debt (Recent Filing)$23.37M

Price to Earnings (P/E)―

Beta8.51

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding31,784,908

10 Day Avg. Volume265,141

30 Day Avg. Volume215,293

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)-3.53

Price to Sales (P/S)0.00

P/FCF Ratio-9.70

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$35.40

Price Target Upside― Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline ValidationThe updated Phase 1/2 results provide meaningful clinical validation for BH-30643 in a difficult, heavily pretreated lung-cancer population. Response, disease control, continued treatment, and tolerability data support further development and could strengthen the pipeline’s strategic value over the next several quarters.

IPO Funding And GovernanceSubstantial IPO proceeds improve the company’s ability to fund clinical development and advance its pipeline without relying immediately on another financing. The accompanying public-company governance changes may also support oversight, transparency, and strategic flexibility as development activities expand.

Expanding Asset BaseGrowth in total assets indicates that the company has expanded its financial resources while progressing its biotechnology program. Although asset growth does not offset negative equity, it provides a larger base to support research, clinical execution, and potential future commercialization efforts.

Bears Say

No Revenue And Widening LossesThe absence of revenue leaves the company dependent on future clinical success, commercialization, or partnerships to establish an operating business. Losses that nearly doubled year over year show that spending demands are rising before any proven revenue stream can support the business.

Heavy And Worsening Cash BurnIncreasing operating and free-cash-flow losses indicate that the company consumes substantial cash to sustain its development activities. Continued burn raises the importance of external funding and can constrain strategic flexibility if clinical programs require more capital than currently expected.

Negative Equity And Rising DebtDeepening negative equity signals accumulated financial pressure, while sharply higher debt adds fixed obligations to a loss-making, pre-commercial business. Together, these conditions weaken balance-sheet resilience and increase dependence on financing to maintain operations and advance the pipeline.

BlossomHill Therapeutics, Inc. News

BlossomHill Therapeutics price target raised to $40 from $36 at Leerink

Leerink raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $36 and keeps an Outperform...

3d ago

BLSM

BlossomHill Therapeutics price target raised to $40 from $30 at Guggenheim

Guggenheim raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $30 and keeps a Buy...

3d ago

BLSM

Midday Fly By: Stocks fall as rate-hike bets boost bond yields

Stocks swung lower on Friday as Treasury yields rebounded and rekindled concerns of a deteriorating macroeconomic backdrop. The...

6d ago

ACN

BlossomHill Therapeutics reports Q2 EPS ($8.75) vs ($5.51) last year

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of...

6d ago

BLSM

BlossomHill Therapeutics announces updated SOLARA trial data

BlossomHill Therapeutics (BLSM) announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell...

9d ago

BLSM

Guggenheim starts BlossomHill Therapeutics with a Buy on pipeline potential

As previously reported, Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target...

23d ago

BLSM

BlossomHill Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $36 price target Published first on...

23d ago

BLSM

BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $32 price target Published first...

23d ago

BLSM

BlossomHill Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target Published first on...

23d ago

BLSM

BlossomHill Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $35 price...

23d ago

BLSM

BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on BlossomHill Therapeutics, Inc.,...

9d ago

BLSM

BlossomHill updates BH-30643 lung cancer trial results

BlossomHill Therapeutics, Inc. ( ($BLSM) ) has issued an announcement. On September 15, 2026, BlossomHill Therapeutics reported updated...

9d ago

BLSM

BlossomHill Therapeutics completes IPO and updates governance

BlossomHill Therapeutics, Inc. ( ($BLSM) ) has issued an update. On August 10, 2026, BlossomHill Therapeutics, Inc. closed...

1M ago

BLSM

BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO

Shares in cancer-focused biotech firm BlossomHill Therapeutics ($BLSM) dropped nearly 3% in its stock market debut after it...

2M ago

BMY

JPM

BLSM FAQ

What was BlossomHill Therapeutics, Inc.’s price range in the past 12 months?

BlossomHill Therapeutics, Inc. lowest stock price was $15.25 and its highest was $27.99 in the past 12 months.

What is BlossomHill Therapeutics, Inc.’s market cap?

BlossomHill Therapeutics, Inc.’s market cap is $802.57M.

When is BlossomHill Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were BlossomHill Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is BlossomHill Therapeutics, Inc. overvalued?

According to Wall Street analysts BlossomHill Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BlossomHill Therapeutics, Inc. pay dividends?

BlossomHill Therapeutics, Inc. does not currently pay dividends.

What is BlossomHill Therapeutics, Inc.’s EPS estimate?

BlossomHill Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BlossomHill Therapeutics, Inc. have?

BlossomHill Therapeutics, Inc. has 31,784,908 shares outstanding.

What happened to BlossomHill Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of BlossomHill Therapeutics, Inc.?

Currently, no hedge funds are holding shares in BLSM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BlossomHill Therapeutics, Inc. Stock Smart Score

Outperform

Company Description

BlossomHill Therapeutics, Inc.

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

BlossomHill Therapeutics, Inc. (BLSM) Earnings & Revenues

Historic Earnings Reports

BLSM Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","28":"$28","41":"$41","21.5":"$21.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,21.5,28,34.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.99,20.606153846153845,22.22230769230769,23.838461538461537,25.454615384615384,27.07076923076923,28.686923076923076,30.303076923076922,31.91923076923077,33.535384615384615,35.151538461538465,36.76769230769231,38.38384615384615,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.99,20.252307692307692,21.514615384615382,22.776923076923076,24.03923076923077,25.30153846153846,26.563846153846153,27.826153846153844,29.088461538461537,30.35076923076923,31.61307692307692,32.87538461538462,34.137692307692305,{"y":35.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.99,19.836923076923075,20.68384615384615,21.53076923076923,22.377692307692307,23.224615384615383,24.07153846153846,24.918461538461536,25.765384615384615,26.61230769230769,27.459230769230768,28.306153846153848,29.153076923076924,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >